Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Posts Flat Q3 Revenues as GeneChip Sales Increase

NEW YORK , Oct. 24 – Affymetrix reported flat third-quarter revenues despite increasing sales of its GeneChip product increased, the company said on Wednesday. 

Affy's overall third-quarter revenues totaled $55.4 million, compared to $55.8 million for the same period one year ago. Product revenue increased to $47.3 million from $45.4 million for the year-ago quarter, the company said. 

This included sales of 70,000 GeneChip arrays, up from 50,000 for the third quarter 2000. The company also shipped 48 GeneChip systems, bringing its total installed base to 540.

A portion of the company’s product revenues, totaling $3.1 million, was derived from sales of GeneChips and related products to spin-off Perlagen Sciences. That company is seeking to perform population-based studies of genetic variation using whole wafers of GeneChips.

Other revenues from research, license fees, and royalties declined to $4.4 million $10.4 million in the third quarter 2000.

This shift in revenues reflects Affymetrix’s implementation an overall altered strategy which President Sue Siegel detailed in the previous quarter’s conference call to focus sales and marketing efforts on its core GeneChip product rather than on arraying equipment and licensing deals.

During the quarter, the company’s overall expenses increased slightly, to $63.2 million, from $57.6 million year over year. This increase includes a rise in R&D costs to $16.6 million from $13.7 million for the third quarter last year, but a decline in selling, general, and administrative costs to $21.4 million from $25.5 million for the year-ago quarter. Other added costs included $4.7million in amortization of stock and purchased intangibles.

Affymetrix’s losses for the quarter totaled $4.8 million, or 8 cents per share, beating Wall Street’s expectations by three cents, according to a poll of nine brokers conducted by FirstCall/Thomson Financial. However, losses would have been greater, if the company had not recorded an extraordinary gain of $1.7 million triggered by its repurchase of convertible subordinated notes.

At the end of the quarter, Affymetrix reported total current assets of $443.1 million. 

Shares in the Santa Clara, Calif.-based company closed up $1.57, or 7.87 percent, to $21.53 in Nasdaq trading on Wednesday.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.